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Abstract
Background: Combined methylmalonic aciduria and homocystinuria, cobalamin(cbl)C deficiency, is a rare disorder
of intracellular vitamin B12(cbl) metabolism caused by mutations in the MMACHC gene. Both genetic and biochemical
approach have been established to diagnose children and fetuses with cblC deficiency, while in China there is no report
of prenatal genetic diagnosis of cblC deficiency. The aim of the present study was to characterize the mutational
spectrum of cblC deficiency and investigate the feasibility of genetic-sequencing-based prenatal diagnosis for
cblC deficiency.
Methods: 10 pedigrees were recruited in this study with the probands clinically and biochemically confirmed
combined methymalonic aciduria and homocystinuria. Peripheral blood samples were collected for MMACHC
genetic test from the probands and their parents (4 probands had already dead) and 50 control subjects. The
entire coding region and adjacent splice sites of MMACHC were sequenced. After the genotypes of the pedigrees
were identified, chorionic villi sampling were performed for 3 high-risk pregnant women for prenatal genetic
diagnosis.
Results: A total of 7 mutations were identified: c.217C > T (R73X), c.394C > T (R132X), c.463G > C (G155R), c.609G > A
(W203X), c.616C > T (R206W), c.658-660delAAG (220delK), and c.567dupT (I190YfsX13), as well as 2 polymophsims:
c.321G > A(V107V), c.-302G > T. And G155R is a novel mutation that haven’t been reported in the literatures. All the 6
probands identified with compound heterozygous mutations or homozygous mutations of MMACHC gene, and
all the parents of the probands were found to have one MMACHC mutation at a heterozygous level. Prenatal
diagnosis of fetuses from 3 families with a child affected cblC deficiency showed that one fetus had the same
compound heterozygous mutations as the proband, one did not have MMACHC mutation, and the third fetus
had a mutation at a heterozygous level of MMACHC gene. Results from the follow-ups were consistent with the
prenatal diagnosis.
Conclusion: A novel mutation p.G155R of the MMACHC gene is identified. Genetic diagonsis is an accurate and
convenient method for prenatal diagnosis and early intervention of combined methylmalonic aciduria and
homocystinuria.
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diagnosis
* Correspondence: kongxd@263.net
Center of Prenatal Diagnosis, the First Affiliated Hospital of Zhengzhou
University, Zhengzhou 450052, People’s Republic of China
© 2015 Zong et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Zong et al. BMC Medical Genetics    
DOI 10.1186/s12881-015-0196-8
Background
Methylmalonic acidemia (MMA), the most common
inborn disorder of organic acid metabolism, is inherited
as an autosomal recessive disease caused by defects of
methylmalonyl CoA mutase (MCM) or disorders of intra-
cellular cobalamin metabolism [1]. MMA can be classified
as isolated methymalonic acidemia and combined methyl-
malonic acidemia and hyperhomocysteinemia based on bio-
chemical features. Combined methymalonic aciduria and
homocystinuria consists of four subtypes, MMACHC(cblC),
MMADHC (cblD combined, cblD-MMA and cblD-HCY),
LMBRD1(cblF) and ABCD4(cblJ) [2]. All of them may
cause the deficiency of methylcobalamin (MeCbl) and
adenosylcobalamin (AdoCbl) and then reduce the activity
of methionine synthase and methylmalonyl CoA mutase
(MCM). Thus both methylmalonic acid and homocysteine
will be accumulated in the blood and urine [3, 4]. In
China, 80 % of patients with MMA are combined
methylmalonic acidemia and hyperhomocysteinemia [5],
among which the cblC type is the most common. The
gene associated with the cblC defect is MMACHC (OMIM
277400), which maps to chromosome region 1p34.1 and
consists of 5 exons and expressing a 5.2 kb mRNA encod-
ing a 282 amino acid protein [6]. To date, 77 mutations
have been identified in this gene, and genotype-phenotype
correlations have been studied [7–10]. Based on the age at
onset, two forms of cblC deficiency have been described
[3, 4]. Early-onset patients present in the first year of life
with feeding difficulties, hypotonia, developmental delay,
seizures, pigmentary retinopathy and anemia. Late-onset
patients exhibit ataxia, dementia, psychosis and other
neurologic symptoms after 4 years old [1, 3].
With the application of tandem mass spectrometry
and gas chromatography–mass spectrometry (GC-MS),
more and more affected children have benefitted from
early diagnosis and treatment, greatly reducing mortality
and morbidity in children with MMA. Although MMA
is a partially treatable disorder, both the high mortality
during the acute phase and the chronic damage to the
nervous system, will lower the quality of patient’s life
and increase the family economic burden. The most ef-
fective intervention is to avoid the birth of children with
MMA through prenatal diagnosis. Many successful tech-
niques for prenatal diagnosis of combined methymalonic
aciduria and homocystinuria have been reported in
China and other countries, including measuring the
activity of methylmalonyl-CoA mutase in the amniotic
fluid, amniotic fluid cells and chorionic cells and
quantification of cbl metabolites in amniotic fluid cells
[11, 12]. In recent years, analysis of acylcarnitine ana-
lysis by electrospray tandem mass spectrometry(ESI/
MS/MS) has been used in prenatal diagnosis. A combin-
ation of genetic and biochemical analyses have been
reported, while in China there is no report of prenatal
diagnosis through simple genetic diagnosis. In the present
study, MMACHC mutations were analyzed in 10 pedi-
grees of combined methymalonic aciduria and homocysti-
nuria (cblC type) and a novel mutation was identified.
Prenatal genetic diagnosis was performed for 3 families.
Methods
Patients
Ten pedigrees were recruited for the study which came to
our hospital, the Third Affiliated Hospital of Zhengzhou
University, and the Children's Hospital of Zhengzhou
from March 2011 to April 2013. There was no consan-
guinity among the children, and none of their parents was
consanguineous marriage. Children from 6 families were
directly diagnosed with combined methymalonic aciduria
and homocystinuria based on clinical features. For the
other four families, the probands were diagnosed postmor-
tem (with complete clinical information), because the four
probands presented severe symptoms within 3 months
and died within 1 years old.
All patients showed different levels of respiratory
infections, feeding difficulties, malnutrition, seizures,
drowsiness, seizures, hypotonia, and psychomotor retard-
ation. Urinary organic acid analysed by gas chromatog-
raphy/mass spectrometry (GC-MS,QP2010, Schimadzu,
Japan) showed high levels of methylmalonic acid. Serum
total homocysteine was elevated determined by fluores-
cence polarization immunoassay (IMX automatic analyzer,-
Abbott, the USA) [13].
This study was approved by the Medical Ethics Commit-
tee in the First Affiliated Hospital of Zhengzhou University.
All of the analyzed samples were obtained with the parents’
informed consent.
DNA extraction
2 ml peripheral venous blood was taken from the 6 pro-
bands and 10 couples of parents, and then anticoagulated
by ethylenediaminetetraacetic acid disodium salt (EDTAK2).
The transabdominal chorionic villi sampling were per-
formed with ultrasonic guidance for the high-risk women
at 10 to 13 + 6 weeks of gestation. Genomic DNA was
extracted from peripheral blood samples and chorionic
villi samples using the DNA extraction kit (TIANGEN
Biotech, Beijing, China) according to the manufacturer’s
instructions.
PCR reactions and DNA sequencing
The coding exons and the flanking introns of theMMACHC
gene were amplified by polymerase chain reaction (PCR).
The PCR primers were described by Lerner-Ellis et al.
[6] (Table 1). The reaction mixture of a final volumn of
25 μL contained 10 × PCR buffer,2.5 mM dNTP, 0.2 μM
of each primer, 1U Taq enzyme, and 50 ng DNA tem-
plate. The amplification program consisted of an initial
Zong et al. BMC Medical Genetics    Page 2 of 6
denaturation at 94 °C for 3 min, followed by 30 cycles at
94 °C for 30s, 57- 62 °C for 40s, and 72 °C for 50s, with a
final extension at 72 °C for 8 min. PCR products were
checked on a 2 % agarose gel and then purified. The direct
sequencing was performed with an ABI3130xl gene
analyzer (Life Technologies, USA) using the ABIBigDye3.1
sequencing kit (Life Technologies, USA) according to
manufacturer’s instructions. Both strands of the shifted
exons were sequenced. Sequences were aligned and
inspected to identify nucleotide variations using a ref-
erence sequence from Ensemble (NM_015506).
Bioinformatics analysis of sequence variations
By searching the HGMD database, Exome Variant Server
and ExAC browser, the new mutations were identified
and the frequency of each known variantion is available.
The analysis software ClustalW was used to compare
the homologous sequences of human MMACHC with
other species. PROVEAN prediction and Polymorphism
Phenotyping (PolyPhen) were performed to analyze the
impact of new mutations. The corresponding fragments
of MMACHC from 50 unrelated healthy individuals
were amplified and sequenced.
Prenatal diagnosis
After the genotype of the probands and their parents
were identified, prenatal genetic diagnosis was performed
for the 3 fetuses at 10 to 13 + 6 weeks’ gestation. DNA was
extracted from chorionic villi samples and mutations of
the MMACHC gene were detected. To exclude contamin-
ation from the mother, the PowerPlex 16 HS System kit
(Promega, Madison, WI, USA) were used and the results
were analyzed using ABI3130xl (Life Technologies, USA)
and the software GeneMapper v3.2. The evaluation cri-
teria for absence of contamination were defined as follows:
the fluorescence peaks of the gene-sites of the fetus were
also appeared in its parents, and there is only one fluores-
cence peak acquired from its mother. The prenatal genetic
diagnosis will be carried out within 1 week.
Follow-up
Specimens of umbilical cord blood or fibroblast cells from
the three fetuses were collected for genetic diagnosis. Or-
ganic acid levels of urine and serum total homocysteine
were detected for two newborns at 1 month old.
Results
Analysis of MMACHC mutations
Nine vatiations in MMACHC were found in the 10
pedigrees (Table 2), two of them were silent gene poly-
morphisms, c.321G >A(V107V), c.-302G > T. Mutations
of c.217C > T, c.394C > T and c.609G >A were nonsense
which resulted in premature termination of translation
at amino acid residue arginine (73), cysteine (132) and
tryptophan (203), respectively. The missense mutation
c.463G > C led to the replacement of glycine (155) with
arginine (Fig. 1). The insertion in c.567dupT resulted in
a frameshift mutation starting from isoleucine (190).
The deletion mutation of c.658 ~ 660delAAG led to the
deletion of lysine during protein translation. The mis-
sense mutation c.616C > T may cause the replacement
of arginine (206) with tryptophan. None of the muta-
tions listed here were found in exon sequencing of the
MMACHC gene from the 50 control subjects. By
searching the ExAC browser and other databases, the
p.G155R mutation have not been reported before, thus
it is considered to be a novel mutation. Comparative
analysis of the amino acid sequence of MMACHC from
human, chimpanzee, zebrafish, rodents, and lizards was
performed, and we found that the residue G155 is
highly conserved between various species (Fig. 2) indi-
cating it might be essential for the normal function of
MMACHC. Another type of mutation has been previously
reported as pathogenic at the same codon, c.464G > A,
p.G155E [14]. Besides the p.G155R mutation was consid-
ered pathogenic as PolyPhen2 software predicted that the
functional consequences was probably damaging (score of
1.000). In addition, the PROVEAN score of the p.G155R
mutation was –7.167 (cutoff:–2.5).
The variation c.-302 T > G located in the 5’ untrans-
lated region, and c.321G > A (V107V) was a synonymous
mutation, both of them are known polymorphisms.
Prenatal diagnosis of MMACHC gene and follow-up
In family 1, the mother of one deceased proband was
found to have 220delK heterozygous mutation and the
father had W203 heterozygous mutation. The fetus was
identified with compound heterozygous mutation of
220delK/W203X, and was affected cblC deficiency. In
family 6, the proband had compound heterozygous muta-
tions of R206W/W203X,while the mother had R206W mu-
tation and the father had W203X mutation respectively.
The fetus was identified as a heterozygous carrier of
R206W mutation. In family 8, the proband had W203X




MMACHC-1 F: Exon 1 GGGATACCGTGATGATACGC 680 bp
MMACHC-1R: GAACCCAGGAGGATCAGAGG
MMACHC-2 F: Exon 2 TGCATCACATAGCGTCAGTG 467 bp
MMACHC-2R: AGCCTGGCTTTAGGGTATCA
MMACHC-3 F: Exon 3 TCATGTTTTCCCTTCTGAGGA 395 bp
MMACHC-3R: CAAAGCTAATTTGTTCTGGGTTG
MMACHC-4 F: Exon 4 AGGCCTAGCTTGCAATGATG 694 bp
MMACHC-4R: GAAGGCAGATGGGAATTCTG
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mutations at a homozygous level, and both the parents
had one W203X allele, while the fetus did not have any
MMACHC mutations (Table 2). Chorionic villi tissues
collected from the fetuses of were analyzed to exclude
maternal contamination using the PowerPlex 16 HS System
kit, thus the results of gene detection in this study was
reliable.
After genetic counseling, family 1 chose to terminate
the pregnancy. The fetal fibroblast cells were collected
for genetic test, and the result were consistent with that
of the prenatal diagnosis. Family 6 and 8 chose to con-
tinue the pregnancies, and the umbilical cord blood was
taken for gene diagnosis after the childbirth. The results
were consistent with that of prenatal diagnosis. Organic
acid levels of urine and serum total homocysteine of the
two newborns were normal at 1 month old.
Discussion
In this study, 9 variations in MMACHC were identified
in 10 pedigrees with cblC deficiency including a novel
mutation, G155R. By transabdominal chorionic villi sam-
pling and DNA sequencing, genetic prenatal diagnose is
performed and proved to be accurate and convenient.
Among 3 cases of prenatal diagnosis, one fetus was found
to be affected by cblC deficiency with compound heterozy-
gous mutations of MMACHC, one fetus was determined
to be a mutation carrier, while the third fetus had a normal
genotype. Genetic sequencing after birth for the second
Fig. 1 DNA sequencing maps. a a positive sequencing of DNA of the probands which shows G / C heterozygous peaks indicating c.463G > C
(G155R) heterozygous mutation; b DNA sequencing of the normal families which shows homozygous peaks. The position with detected mutation is
indicated with arrow














(age and clinical details)
1*# / 220delK W203X 1 months 43 20.8 NA. Dead of severe malnutrition at
6 months old
W203X, 220delK
2 R132X W203X R132X 6 months 99 187.3 Normal^ 1.5y,developmental delay HC
decreased to 60 μM
W203X
3 G155R G155R c.567dupT 1 month NA 75.1 nystagmus MMA decreased to 24.6 μM
c.567dupT
4# / W203X 220delK 3 weeks NA. Dead at 1 month old
5# / R73X 220delK 2 months NA. Dead at 8 month old
6* R206W R206W W203X 40 days 158 45.1 nystagmus 3y,developmental delay, R206W,
W203X HC, MMAare normal ——
7 W203X W203X 220delK 10 days 131 958.9 nystagmus developmental delay, malnutrition
220delK
8* W203X W203X W203X 2 weeks 174 215.2 Normal^ 15 months, taking medicine promptly and
properly for a period of time, the patient has
being in good recovery
——,
W203X ——
9# / 220delK W203X NA. NA. Dead at 4 months old
10 W203X W203X W203X 3 months 108 29.4 Visual
inattention
nystagmus
6 months, Can’t raise his head, developmental
delay
W203X
Note: *indicates prenatal diagnosis families; # indicates the proband in the family was dead; / indicates that the genotype of the dead proband was not available;
——indicates no mutation was detected; ^ indicates the proband’s parents said it’s normal without test
HC:value of serum homocysteine (reference value:5-15 μM)
MMA:value of urine methylmalonic acid (reference value:0.2-3.6 μM)
NA.:not avaliable,bacause the patient is from other hospital or can’t get through telephone
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and the third babies confirmed the results of prenatal
diagnosis.
To date, 77 diferent mutations in the MMACHC gene
have been reported. Among these mutations, several mu-
tations are common but ethnic-specific. The c.271dupA
mutation is the most common allele in Europeans, with a
mutation frequency of 40 %, and ususlly occurred in early-
onset cases. The c.394C > T mutation at a homozygous
level occurred mostly in Native American and Middle
Eastern patients, and is associated mostly with a late-onset
disease [8, 9]. The mutation c.609G > A (W203X) oc-
curred most frequently in patients in East Asia [15–17].
Han [16] reported that 156 mutations were found in
158 disease alleles in 79 Chinese patients with combined
methymalonic aciduria and homocystinuria. The muta-
tions c.609G > A (W203X), c.658_660delAAG (K220del),
c.482G > A (R161Q), c.394C > T (R132X), and c.80A > G
(Q27A) were the most frequent and accounted for 80 %
of all mutations. Among these 5 mutations, the c.609G >A
mutation was the most common, accounting for 50 %,
followed by the c.658_660delAAG mutation, which
accounted for 9 %. In this study, 10 c.609G > A muta-
tions were found in 20 alleles accounting for 50 % of
the total mutations, which further confirmed that the
c.609G > A mutation in MMACHC was the hot spot in
Chinese patients. Another recent study proposed that
the c.609G > A mutation may be specific to East Asian
populations [10].
A total of seven mutations and two polymorphisms
were detected in this study. The mutations c.217C > T,
c.394C > T and c.609G > A lead to the encoding of a stop
codon at amino acid residue 73,132 and 203 resulting in
premature termination of translation. The c.658_660delAAG
mutation, located in the C-terminal region of MMACHC,
causes deletion of lysine at residue 220. The c.616C >T
(R206W) mutation is first reported in China, and its
function have not been reported so far. The c.567dupT
mutation causes a frameshift at codon 189 and a premature
termination at codon 202. The c.463G >C (G155R) muta-
tion is reported for the first time although c.464G >A
(p.G155E) mutation at the same codon has been reported
previously [14]. The MMACHC glycine 155 is highly con-
served among many species and PROVEAN and PolyPhen
analysis for p.G155E suggested pathogenic. Among seven
mutations found in this study, six were located in exon 4.
Liu et al. [15] showed that exon 3 and exon 4 are mutation
hot spots. Therefore genetic screening of cbl deficiency
may be performed preferentially in exon 3 and exon 4 of
MMACHC.
In general, late-onset patients have better survival and
response to treatment compared with early-onset pa-
tients. As an early-onset patient, patient 6 in this study
had been given treatment with hydroxycobalamin, carni-
tine, betanine and folinic acid, as well as rehabilitation
programs promptly after diagnosis. During follow-up at
3 years old, we found that his urine levels of MMA de-
creased to normal and plasma levels of homocystenuria
decreased to 10.6 μmol/l. The result confirmed the im-
portance of early intervention of the disease.
In this study, 3 families with probands affected the
early-onset cbl deficiency underwent prenatal genetic
diagnosis. W203X mutation was found at a homozygous
level in one family, and at a heterozygous level for the
other two families. Wang reported that in 31 cases of
early-onset cbl C deficiency, 25 (80.6 %) had the W203X
mutation, indicating that the W203X mutation may be
associated with early-onset phenotype [16]. However,
more data are needed to confirm this correlation.
The early-onset cbl deficiency is a severe neonatal gen-
etic disease. Although the outcome will be better through
early detection and treatment, most children die before
one year old. Prenatal diagnosis is helpful and necessary to
parents who want a second child. In families with de-
ceased probands, genetic diagnosis can be made by testing
the parental MMACHC genes. If both of the parents have
a MMACHC mutation at a heterozygous level, the pro-
band’s genotype can be deduced. Prenatal diagnosis for cbl
deficiency is sought for terminating an affect pregnancy,
instituting treatment during pregnancy or alleviating men-
tal pressure of the couples and so on. Prenatal OHCbl
Fig. 2 MMACHC protein sequences from different organisms. The G155 in MMACHC is highly conserved between humans, gorillas, zebrafish,
rodents, and lizards. Amino acid region 139-188 of human protein sequences are shown
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administration may reduce the maternal metabolites,
however the complications of cbl deficiency such as
retinopathy could not be ameliorated [3]. In this study,
chorionic villi samples were collected in the first-trimester
pregnancy for prenatal genetic diagnosis for 3 families.
The fetus of the first family was identified with 220delK/
W203X compound heterozygous mutation and the
parents chosed terminate the pregnancy. After abortion
the fibroblast cells of that fetus were tested for MMACHC
mutations, and the results were consistent with the
prenatal diagnosis. The fetus of the second family had
R206W mutation at a heterozygous level, while the third
fetus was normal. After genetic counseling, the two
families decided to continue their pregnancies. After the
babies were born, they were determined to be healthy by
physical examination and laboratory tests. There are
several approaches to make biochemical prenatal diag-
nosis of MMA [17]. Reaserchers could determine the
methylmalonate in amniotic fluid(AF) and maternal
urine, measure the mutase reaction and cobalamin metab-
olism in cultured amniocytes, study the [14C]-propionate
incorpation, analysis acylcarnitine, and assay the MCM ac-
tivity in chorionic villi(CV) [18]. There seems to be a lack
of consensus on the most reliable method, and preferred
sample on which to conduct these investigations. And it is
reported that the results could be false nagtive/positive [2,
17]. Although the metabolic analysis of amniotic fluid will
be carried out simply, the molecular genetic testing is the
best method to make prenatal diagnose in the first trimis-
ter,since amniocentesis shouldn’t be performed before the
16th gestational week to avoid complications. Our success
with prenatal genetic diagnosis of cblC deficiency shows
that it is acurate and economical. It could also be an ef-
fective method of genetic screening for affected families.
But the information of the proband or its parents must be
avaliable, and maternal contamination of the DNA sample
should be excluded by marker analysis. Preimplantation
genetic diagnosis could also be considered for the families
whose pathogenic mutation have been identified.
Conclusions
We present the molecular confirmation of infantile on-
set cobalamin C type-combined methylmalonic acidemia
and homosystinuria in 6 probands and their parents,
as well as 4 additional couples with diseased children
affected cblC deficiency, and a novel mutation of the
MMACHC gene, p.G155R is identified. We also per-
formed prenatal diagnosis using CVS(chorionic villi sam-
pling) and DNA sequencing for three high-risk pregnant
women successfully.
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